More Stories

Informist, Tuesday, Aug. 5, 2025

--Gland Pharma Apr-Jun consol revenue INR 15.06 bln vs INR 14.02 bln yr ago 

--Gland Pharma Apr-Jun consol net profit INR 2.15 bln vs INR 1.44 bln yr ago 

--Analysts saw Gland Pharma Apr-Jun consol net profit INR 2.06 bln

--Gland Pharma Apr-Jun consol net profit INR 2.15 bln 

By Rati Chaphekar

MUMBAI - Gland Pharma Ltd. posted a robust growth in net profit for the quarter ended June due to improvement in margins and a substantial fall in its inventory cost. A fall in sales from the US market during the quarter, which is the biggest contributor to top line, was offset by robust sales growth in other geographies such as Europe, Canada, Australia, and New Zealand. The company also outperformed analysts' expectation in revenue, posting a modest growth. 

The pharmaceutical company reported a consolidated net profit of INR 2.15 billion for the reporting quarter, up nearly 50% on year and 15.5% on quarter. The company outperformed the analysts' bottom line expectation of INR 2.06 billion. It posted consolidated revenue from operations of INR 15.06 billion, up 7.4% on year and 5.7% on quarter. The company marginally outperformed the analysts' revenue expectation of INR 15.05 billion.

Its total expenses rose to INR 12.5 billion, up marginally on year and 5.9% higher on quarter. The company saw a sharp fall in purchase of stock-in-trade to INR 8.81 million, down 86.6% on year and 71.6% on quarter, from 65.83 million in the year-ago quarter. The company's cost of changes in inventories of finished goods, stock-in-trade and work-in-progress was at (-) INR 371.08 million compared to INR 960.22 million in the year-ago quarter. Employee benefit expenses rose to INR 4.08 billion, up 14.8% on year and 9.3% on quarter. The company saw a sharp rise in finance cost to 115 million, up 104.7% on year and 54.3% on quarter. 

The company's earnings before interest, tax, depriciation, and amortisation for the quarter came in at INR 3.68 billion, up 39% on year and 6% on quarter. EBITDA margin for the June quarter was 24%, up 500 bps on year. 

Gland Pharma's sales from the Canada, Australia and New Zealand markets rose 65% on year to INR 739 millon during the quarter. The India market posted a revenue of INR 594 million, up 13% both on year and sequentially, mainly driven by volume growth in existing products, including the drug Huminsulin. The company's US business sales decreased marginally on year. The US operations accounted for 49% of the company's total revenue in the reporting quarter.

The shares of the company ended at INR 1,964.70 on the National Stock Exchange on Tuesday, down marginally. The company announced its June quarter earnings post market hours.  End

Edited by Vandana Hingorani

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.